PACKAGE LEAFLET: INFORMATION FOR THE USER
Paracetamol Kabi 10 mg/ml, solution for infusion EFG
Read all of this leaflet carefully before you start using this medicine because it contains important information for you:
Contents of the pack:
This medicine is a pain reliever (analgesic) and a fever reducer (antipyretic).
It is indicated
Do not use Paracetamol Kabi
Warnings and precautions
Consult your doctor before using Paracetamol Kabi.
During treatment with Paracetamol Kabi, inform your doctor immediately if:
If you have severe diseases, such as severe renal failure or sepsis (when bacteria and their toxins circulate in the blood, causing damage to organs), or if you suffer from malnutrition, chronic alcoholism or if you are also taking flucloxacillin (an antibiotic). A severe disease called metabolic acidosis (an anomaly in the blood and fluids) has been reported in patients in these situations when paracetamol is used at regular doses for a prolonged period or when paracetamol is taken with flucloxacillin. The symptoms of metabolic acidosis may include: severe breathing difficulties with deep and rapid breathing, drowsiness, feeling of discomfort (nausea) and vomiting.
Be careful with Paracetamol Kabi
Before treatment, inform your doctor if any of the above conditions apply to you.
You should take analgesics in tablets or syrup instead of Paracetamol Kabi as soon as possible.
Other medicines and paracetamol:
During treatment with Paracetamol Kabi, do not take other medicines that contain paracetamol, this should be taken into account to not exceed the recommended daily dose (see the next section). Inform your doctor if you are taking other medicines that contain paracetamol.
If you are being treated with probenecid(a medicine used to treat gout), your doctor should consider a reduction in the necessary dose of paracetamol since probenecid increases paracetamol levels in the blood.
Salicylamide(another pain reliever) may increase paracetamol levels in the blood and therefore may increase the risk of its toxic effects.
Rifampicin, isoniazid(antibiotics), barbiturates(sedatives), tricyclic antidepressantsand medicines for treating epileptic seizures(antiepileptics such as carbamazepine, phenytoin, phenobarbital, primidone) may reduce the analgesic and antipyretic effect of paracetamol and, like alcohol, may increase its toxic effects on the liver.
In case of taking paracetamol at the same time as chloramphenicol(an antibiotic), the action of the latter may be prolonged.
Please inform your doctor or pharmacist if you are taking oral contraceptivesbecause they may reduce the action of paracetamol.
Taking paracetamol with zidovudine(a medicine used to treat HIV) increases the risk of reduction of certain white blood cells (neutropenia). Therefore, it increases the risk of infections.
Please inform your doctor or pharmacist if you are taking oral anticoagulants(substances that reduce blood clotting speed). More analyses may be necessary to evaluate the effect of the anticoagulant.
Inform your doctor or pharmacist if you are taking flucloxacillin(an antibiotic), due to a serious risk of blood and fluid disorder (called metabolic acidosis) that requires urgent treatment (see section 2).
Inform your doctor or pharmacist if you are using or have recently used any other medicine, even those purchased without a prescription.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
If necessary, Paracetamol Kabi can be used during pregnancy. You should use the lowest possible dose that reduces pain or fever and use it for the shortest possible time. Contact your doctor if the pain or fever does not decrease or if you need to take the medicine more frequently.
Breastfeeding
Paracetamol Kabi can be used during breastfeeding.
Driving and using machines
No effects on driving and using machines have been described.
This medicine is administered intravenously.
Paracetamol Kabi will be administered by your doctor. It is administered through a drip (infusion).
The 100 ml vial or bag is restricted to adults, adolescents and children who weigh more than 33 kg (approximately 11 years).
The 10 ml ampoule, 50 ml vial or bag is restricted to full-term newborns, infants and children who weigh less than 33 kg.
Careful supervision is necessary before finishing the infusion, to avoid air entering the vein.
Dosage
Dose according to patient weight (see the posology table below)
Patient weight | Dose per administration | Volume per administration | Maximum volume of Paracetamol Kabi (10 mg/ml) per administration according to the upper weight limits of the group (ml)*** | Maximum daily dose ** |
≤ 10 kg* | 7.5 mg/kg | 0.75 ml/kg | 7.5 ml | 30 mg/kg |
> 10 kg to ≤33 kg | 15 mg/kg | 1.5 ml/kg | 49.5 ml | 60 mg/kg not exceeding 2 g |
> 33 kg to ≤50 kg | 15 mg/kg | 1.5 ml/kg | 75 ml | 60 mg/kg not exceeding 3 g |
> 50 kg with additional risk factors for hepatotoxicity | 1 g | 100 ml | 100 ml | 3 g |
> 50 kg and without additional risk factors for hepatotoxicity | 1 g | 100 ml | 100 ml | 4 g |
*Preterm infants:There is no data on efficacy and safety in preterm infants.
**Maximum daily dose:The maximum daily dose described in the table above is for patients who are not taking other medicines with paracetamol and should be adjusted accordingly taking into account these medicines.
***Patients who weigh less will require smaller volumes.
Do not administer more than 4 doses in 24 hours.
Method of administration
RISK OF MEDICATION ERRORS Be careful to avoid dosing errors due to confusion between milligrams (mg) and milliliters (ml), which can cause accidental overdose and death. |
Paracetamol Kabi solution is administered by infusion (through a drip) in your vein for about 15 minutes. An interval of at least 4 hours should be left between each administration.
If you think the action of Paracetamol Kabi is too strong or too weak, tell your doctor.
If you use more Paracetamol Kabi than you should
If you have taken more Paracetamol Kabi than you should, consult your doctor or pharmacist immediately.
The most frequent symptoms in case of overdose appear during the first 24 hours and are: nausea, vomiting, anorexia, pallor and abdominal pain. In case of overdose, immediately inform the medical staff due to the risk of irreversible liver damage.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Paracetamol Kabi can cause side effects, although not everybody gets them.
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(cannot be estimated from the available data):
Effects on laboratory tests
Treatment with Paracetamol Kabi may alter the results of some tests such as the determination of uric acid, as well as blood glucose analysis.
If you notice any side effect, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep Paracetamol Kabi out of the sight and reach of children.
Do not use Paracetamol Kabi after the expiry date stated on the packaging after EXP. The expiry date refers to the last day of the month.
Do not refrigerate or freeze.
Before administration, the product must be visually inspected.
Do not use Paracetamol Kabi if you observe the presence of particles or if the solution has discolored beyond a slight yellow.
Your doctor or hospital healthcare staff will normally store Paracetamol Kabi and are therefore responsible for the quality of the product when it has been opened and not used immediately. However, if it is not used immediately, the product can be stored for up to a maximum of 24 hours. After dilution, the solution should not be stored for more than 6 hours (including infusion time). They are also responsible for the correct disposal of Paracetamol Kabi residues.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Paracetamol Kabi
Appearance of Paracetamol Kabi and Container Contents
Paracetamol Kabi 10 mg/ml, solution for infusion is a slightly yellowish transparent solution.
Paracetamol Kabi 10 mg/ml, solution for infusion is presented in 10 ml glass ampoules and 50 ml or 100 ml glass vials closed with aluminum/plastic flip-off caps or in 50 and 100 ml bags with plastic closures and covers that allow verification if they have been tampered with.
Containers:
Ampoules:
10 ampoules
Vials:
1 vial
10 vials
12 vials
20 vials
Bags:
20 bags
50 bags
60 bags
Only some container sizes may be marketed.
Marketing Authorization Holder and Manufacturer:
Marketing Authorization Holder:
Fresenius Kabi España, S.A.U.
Marina 16-18
08005 – Barcelona (Spain)
Manufacturer:
Fresenius Kabi Deutschland GmbH
Plant Friedberg
Freseniusstrasse 1
D-61169 Friedberg
Germany
Fresenius Kabi Austria GmbH
Hafnerstrasse, 36 - A-8055
Austria (GRAZ)
Fresenius Kabi France
6, Rue de Rempart
F-27400 Louviers
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Austria | Paracetamol Kabi 10 mg/ml Infusionslösung |
Belgium | Paracetamol Fresenius Kabi 10 mg/ml oplossing voor infusie |
Bulgaria | ??????????? ???? 10 mg/ml ?????????? ??????? |
Cyprus | Paracetamol/Kabi |
Czech Republic | Paracetamol Kabi |
Denmark | Paracetamol “Fresenius Kabi” |
Estonia | Paracetamol Kabi 10 mg/ml |
Finland | Paracetamol Fresenius Kabi |
Germany | Paracetamol Kabi 10 mg/ml Infusionslösung |
Greece | Paracetamol Kabi |
Hungary | Paracetamol Kabi 10 mg/ml |
Ireland | Paracetamol 10 mg/ml solution for infusion |
Italy | Paracetamolo Kabi 10 mg/ml |
Latvia | Paracetamol Kabi 10 mg/ml škidums infuzijam |
Lithuania | Paracetamol Kabi 10 mg/ml infuzinis tirpalas |
Luxembourg | Paracetamol Kabi 10 mg/ml Infusionslösung |
Norway | Paracetamol “Fresenius Kabi” 10 mg/ml infusjons-væske, oppløsning |
Poland | Paracetamol Kabi |
Portugal | Paracetamol Kabi |
Romania | Paracetamol Kabi 10 mg/ml, solutie perfuzabila |
Slovakia | Paracetamol Kabi 10 mg/ml |
Slovenia | Paracetamol Kabi 10 mg/ml raztopina za infundiranje |
Spain | Paracetamol Kabi 10 mg/ml solución para perfusión |
Sweden | Paracetamol Fresenius Kabi |
The Netherlands | Paracetamol Fresenius Kabi 10 mg/ml oplossing voor infusie |
UK | Paracetamol 10 mg/ml solution for infusion |
This leaflet was last revised inJanuary 2025
--------------------------------------------------------------------------------------------------------------------
The following information is intended for healthcare professionals only:
Handling
This medicinal product is for single use. All unused solution remains must be discarded.
Before administration, the product must be visually inspected for the absence of particles or discoloration.
The 100 ml vial or bag is restricted to adults, adolescents, and children weighing more than 33 kg.
The 10 ml ampoule and the 50 ml vial or bag are restricted to full-term newborns, infants, and children weighing less than 33 kg.
As with all infusion solutions presented in glass vials or bags, careful monitoring is necessary, especially at the end of the infusion, regardless of the infusion route. This monitoring at the end of the infusion is particularly important in the case of central infusions to avoid gas embolias.
Compatibility
Paracetamol Kabi 10 mg/ml solution for infusion can be diluted in a 9 mg/ml (0.9%) sodium chloride solution or in a 50 mg/ml (5%) glucose solution up to one-tenth (one volume of Paracetamol Kabi 10 mg/ml solution for infusion in nine volumes of diluent). In this case, the diluted solution must be used within 6 hours of preparation (including infusion time).
The diluted solution must be visually inspected and not used if opalescence, visible particles, or precipitate are observed.
Elimination
Any unused product or waste material must be disposed of in accordance with local regulations.